Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Bora Group 3Q26: Revenue and Net Income Expansion Continues U.S. Manufacturing and Biologics Footprint Complete; Margin Expansion to Follow as Utilization Improves

HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Bora Pharmaceuticals ("Bora"; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 3Q2026 and provides 2027 outlook update . 3Q26 Business and Financial Highlights Record quarterly revenue of NT$6,453 million, up 9.6% QoQ; basic EPS of NT$4.79, up 9.9% QoQ. Building on 2Q26 momentum, revenue…

Bora Group 3Q26: Revenue and Net Income Expansion Continues U.S. Manufacturing and Biologics Footprint Complete; Margin Expansion to Follow as Utilization Improves

Bora Pharmaceuticals reported record quarterly revenue of NT$6,453 million for 3Q2026, marking a 9.6% increase from the previous quarter. The company's basic earnings per share (EPS) also grew 9.9% quarter-over-quarter to NT$4.79. Bora's first-half results showcased impressive growth, with CDMO wins spanning across various product categories in the U.S., Canada, and Taiwan.

The company's backlog of CDMO orders reached US$340 million as of the end of 3Q26, reflecting a healthy build due to site conversions and maintenance shutdowns. Pharma sales revenues increased 12.5% quarter-over-quarter and 9.3% year-over-year, driven by strong performance in specialty and brand franchises. The group expects margin expansion as utilization improves and new technology transfers are completed in U.S. facilities.

Share capital rose 0.3% during the quarter due to employee stock option exercises. Bora's Chairman, Bobby Sheng, emphasized the company's focus on executing commercial technology transfers and delivering on quality commitments. The acquisitions made between 2024 and 2026 have broadened Bora's offerings and are expected to convert into commercial revenue over the next 3 to 5 years.

Despite elevated financing costs weighing on net profit, Bora is nearing the end of the current investment cycle and anticipates favorable conditions as biologics demand shifts in favor of the company.

Written by urgent.news from Arabian Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at thearabianpost.com →

More in Finance & Markets

More from Tuesday 17 November →